By Counterforce Health Team in Gamifant (emapalumab-lzsg) —

How to Get Gamifant (Emapalumab-lzsg) Covered by Blue Cross Blue Shield in New York: Complete Prior Authorization and Appeal Guide

Answer Box: Getting Gamifant Covered in New York

Blue Cross Blue Shield plans in New York cover Gamifant (emapalumab-lzsg) for primary HLH with prior authorization. The fastest path: (1) Submit PA with complete HLH-2004 diagnostic criteria documentation and proof of conventional therapy failure, (2) Use Empire/Excellus provider portal with clinical criteria CC-0087, (3) If denied, file internal appeal within plan deadlines, then external appeal through NY DFS within 4 months. First step today: Download your plan's Gamifant policy and PA form from the provider portal to confirm exact requirements.

Table of Contents

  1. Coverage Requirements at a Glance
  2. Step-by-Step: Fastest Path to Approval
  3. Medical Necessity Documentation
  4. Common Denial Reasons & How to Fix Them
  5. New York Appeals Process
  6. Costs & Patient Support Options
  7. When to Escalate to State Regulators
  8. Frequently Asked Questions

Coverage Requirements at a Glance

Requirement What It Means Where to Find It Source
Prior Authorization Required before first infusion Plan provider portal Empire BCBS NY Clinical Criteria
Primary HLH Diagnosis Must meet HLH-2004 criteria (≥5/8) or genetic confirmation Medical records, genetic testing BCBS Medical Policy
Conventional Therapy Failure Refractory/recurrent disease after etoposide + dexamethasone Treatment history documentation FEP Blue Policy
Specialist Prescriber Hematologist/oncologist or HLH specialist Provider credentials UnitedHealth Policy
Concomitant Dexamethasone Must be given with dexamethasone Treatment protocol FDA Label
Site of Care Hospital outpatient or infusion center Facility certification Plan provider manual

Step-by-Step: Fastest Path to Approval

1. Verify Your Exact Plan and Policy

Who does it: Clinic staff
Timeline: Same day
Action: Log into your Blue Cross Blue Shield provider portal (Empire, Excellus, or Highmark) and locate clinical criteria CC-0087 for Gamifant. Download the current policy PDF.

2. Gather HLH-2004 Diagnostic Evidence

Who does it: Clinician
Timeline: 1-2 days
Documents needed:

  • Lab values with dates: ferritin ≥500 μg/L, soluble CD25 ≥2,400 U/mL
  • Bone marrow biopsy showing hemophagocytosis
  • Evidence of fever, splenomegaly, cytopenias
  • Genetic testing results (if available)

3. Document Conventional Therapy History

Who does it: Clinician
Timeline: 1 day
Required evidence:

  • Treatment dates and doses of etoposide + dexamethasone
  • Response measurements (ferritin trends, CBC changes)
  • Specific reasons for failure/intolerance
  • Duration of therapy (minimum 2 weeks typically required)

4. Submit Prior Authorization Request

Who does it: Clinic staff
Timeline: Submit within 24-48 hours
Method: Provider portal or fax to specialty pharmacy PA department
Include: Completed PA form, clinical notes, lab results, treatment history

5. Follow Up on Determination

Who does it: Clinic staff
Timeline: Standard 72 hours, expedited 24 hours
Action: Check portal daily for status updates. Request expedited review if clinically urgent.

6. Prepare Appeal Strategy (If Denied)

Who does it: Clinician + staff
Timeline: Begin immediately after denial
Focus areas: Address specific denial reasons, strengthen medical necessity documentation, request peer-to-peer review

7. File External Appeal if Needed

Who does it: Patient or provider
Timeline: Within 4 months of final internal denial
Method: NY DFS External Appeal Application

Medical Necessity Documentation

Clinician Corner: Letter of Medical Necessity Checklist

Your letter should address these key elements that Blue Cross Blue Shield medical directors look for:

Diagnosis Section:

  • State explicitly: "Patient meets [X] of 8 HLH-2004 diagnostic criteria"
  • List specific criteria met with lab values and dates
  • Include genetic testing results if available
  • Differentiate primary vs. secondary HLH

Treatment History:

  • Document specific conventional therapy regimen used
  • Include dates, doses, and duration of treatment
  • Quantify lack of response with objective measures
  • Note any contraindications to further conventional therapy

Clinical Rationale:

  • Reference FDA indication for primary HLH
  • Cite plan's own medical policy criteria
  • Explain urgency and consequences of delayed treatment
  • Document plan for stem cell transplant evaluation

Monitoring Plan:

  • Infection screening and prophylaxis protocols
  • Response monitoring schedule
  • Safety monitoring parameters

Common Denial Reasons & How to Fix Them

Denial Reason How to Overturn Documents to Submit
"Insufficient documentation of HLH diagnosis" Submit complete HLH-2004 criteria checklist Lab flowsheet, bone marrow report, genetics
"No evidence of conventional therapy failure" Provide detailed treatment timeline Progress notes, response data, toxicity records
"Secondary HLH not covered" Clarify primary vs. secondary classification Genetics, family history, specialist consultation
"Experimental/investigational use" Reference FDA approval and plan policy FDA label, medical policy excerpt
"Not prescribed by appropriate specialist" Verify prescriber credentials CV, board certification, hospital privileges

New York Appeals Process

Internal Appeal (Required First Step)

  • Deadline: Per plan terms (typically 30-60 days)
  • Method: Provider portal or written request
  • Timeline: 30 days standard, 72 hours expedited
  • Required: New clinical evidence addressing denial reasons

External Appeal Through NY DFS

New York offers robust external appeal rights through the Department of Financial Services:

  • Eligibility: After final internal denial for "not medically necessary"
  • Deadline: 4 months from final internal denial
  • Cost: $25 fee (waived for hardship, refunded if overturned)
  • Timeline: 30 days standard, 72 hours expedited, 24 hours for urgent drug denials
  • Application: Download NY DFS External Appeal Form
Note: DFS decisions are binding on the insurer. New York's external appeal program has successfully overturned many specialty drug denials.

Getting Help with Appeals

Costs & Patient Support Options

Manufacturer Support

Gamifant Cares Program provides:

  • Benefits verification and prior authorization support
  • Reimbursement assistance and appeals help
  • Financial assistance for eligible patients
  • Access: Gamifant.com/navigating-coverage

Additional Resources

  • Patient assistance foundations for rare disease medications
  • Hospital charity care programs
  • State pharmaceutical assistance programs

When to Escalate to State Regulators

Contact NY Department of Financial Services if:

  • Plan violates appeal timelines
  • External appeal decision is ignored
  • Procedural violations occur

File complaint: NY DFS Complaint Portal

Frequently Asked Questions

How long does Blue Cross Blue Shield PA take in New York? Standard review is 72 hours for medical benefit drugs. Expedited review (for urgent cases) is 24 hours. Submit complete documentation to avoid delays.

What if Gamifant is non-formulary on my plan? Most BCBS plans cover Gamifant under the medical benefit (not pharmacy), so formulary status may not apply. Verify through your provider portal.

Can I request an expedited appeal? Yes, if delay would seriously jeopardize the patient's health. Document clinical urgency clearly in your request.

Does step therapy apply to Gamifant? Yes, most plans require failure of conventional HLH therapy (etoposide + dexamethasone) unless contraindicated.

What diagnosis codes should I use? Primary HLH typically uses ICD-10 D76.1 (Hemophagocytic lymphohistiocytosis). Verify with your plan's medical policy.

How do I find past external appeal decisions for similar cases? Search the Community Health Advocates database by service type "pharmacy" and issue "not medically necessary."

From Our Advocates: In our experience helping families navigate HLH treatment approvals, the most successful cases include a comprehensive timeline showing exactly when conventional therapy was tried, what the response was, and why it failed. Plans respond well to objective data like ferritin trends and clear documentation of disease progression. This approach has helped many families get approval within the initial review period.

How Counterforce Health Can Help

Counterforce Health specializes in turning insurance denials into successful appeals for complex medications like Gamifant. Our platform analyzes your specific denial letter and Blue Cross Blue Shield policy to create targeted, evidence-backed appeals that address each denial reason with the right clinical citations and procedural requirements. We help patients, clinicians, and specialty pharmacies navigate the complex prior authorization landscape for rare disease treatments.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions depend on individual circumstances and plan terms. Always consult with your healthcare provider and review your specific insurance policy. For personalized assistance with appeals and prior authorization, consider working with Counterforce Health or contacting Community Health Advocates at 888-614-5400.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.